Prescription Drugs: Emailed Statement and America Corp

prescription drugs: Deliberations are at an early stage, and there's no certainty they will result in a transaction, according to the sources, according to The Japan Times. No decisions have been made regarding specific assets for potential disposal at this stage, a spokeswoman for Takeda said in an emailed statement. The company is working with Bank of America Corp. to gauge potential buyer interest in emerging-market assets it acquired through its 2011 purchase of Swiss rival Nycomed, according to the sources, who asked not to be identified because the information is private. ; The medicines, which include over-the-counter and prescription drugs, could fetch about 3 billion, the sources said. A representative for Bank of America declined to comment. It also doubled the Japanese firm's borrowing level and prompted S&P Global Ratings and Moody's Investors Service to cut its credit rating. Takeda's takeover of Shire, completed earlier this month, vaulted it into the ranks of the world's 10 biggest drugmakers and brought lucrative therapies for rare diseases. (news.financializer.com). As reported in the news.